Navigation Links
MedQuist Reports Second Quarter 2008 Results
Date:8/8/2008

income taxes $263 $276

Accommodation payments paid with credits $611 $1,288

MedQuist Inc. and Subsidiaries

Reconciliation of GAAP financial measures to the aforementioned non-GAAP

measures

Operating Income (Loss), excluding cost of investigation and legal

proceedings, net

(In thousands, except per share amounts)

Unaudited

Three months ended Six months ended

March 31, June 30,

2008 2007 2008 2007

GAAP operating income (loss) $1,848 $4,184 $(3,586) $888

Add: Cost of investigation and legal

proceedings, net 1,728 (6,638) 8,126 (4,897)

Non-GAAP operating income (loss),

excluding Cost of investigation

and legal proceedings, net $3,576 $(2,454) $4,540 $(4,009)

MedQuist Inc. and Subsidiaries Reconciliation of GAAP financial measures to the aforementioned non-GAAP

measures
Cost of investigation and legal proceedings, excluding insurance recoveries
(In thousands, except per share amounts)

Unaudited

Three months ended Six months ended

March 31, June 30,

2008 2007 2008 2007

GAAP Cost of investigation and legal

proceedings, net $1,728 $(6,638) $8,126 $(4,897)

Add: Insurance recoveries - 11,850 - 15,386
'/>"/>

SOURCE MedQuist, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. MedQuist Announces Changes to Board of Directors
2. MedQuist Announces Declaration of $2.75 per share Dividend on Common Stock
3. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
4. MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO
5. MedQuist to Get New Majority Stakeholder
6. MedQuist Technology Solutions to Power Documentation Workflow at New England Facility
7. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
8. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
9. MedQuist Announces Appointment of Brian ODonoghue and Mark E. Schwarz to its Board of Directors
10. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
11. MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
(Date:12/26/2014)... CA (PRWEB) December 26, 2014 Cooking ... 3.1 out of 5. This score reflects slightly positive negotiation ... specialization, low switching costs and a low level of price ... of substitutes for cooking and warming equipment and high volatility ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... Food and Drug Administration as a palliative treatment for ... are sometimes used off-label for the treatment of peripheral ... the American Journal of Therapeutics finds that off-label use ... of adverse events and device malfunctions associated with the ...
... it from experience: After so many hours of being awake, ... of sleep will refresh it., Now new research from the ... this phenomenon, supporting the idea that sleep plays a critical ... its environment. This ability, called plasticity, is at the heart ...
... consortium of clinical scientists and genomics experts, including researchers ... Montral (UdeM), have uncovered multiple new genetic risk factors ... The large-scale genomic study is the first of its ... John D. Rioux, associate professor of medicine at the ...
... of "good" cholesterol , , SATURDAY, Jan. 19 (HealthDay News) ... vehicle,s exhaust may be the most dangerous to your ... that are about one-thousandth the size of a human ... a University of California, Los Angeles-led study. This condition, ...
... Jan. 18 Following the New Hampshire primary,a headline ... life.", Ironically, Joe Dolphin, who announced his endorsement ... a lung transplant, is also hoping,to receive breath that ... leader has suffered for many years with AAT (Alpha-1 ...
... aggressive disease in 2 men taking the product , , ... product described as a dietary supplement appears to have ... two men, researchers report. , "There were things on ... components in the product that were not on the ...
Cached Medicine News:Health News:Study looks at off-label use of biliary stents 2Health News:Study: Brain connections strengthen during waking hours, weaken during sleep 2Health News:Study: Brain connections strengthen during waking hours, weaken during sleep 3Health News:Lupus in women: New genetic risk factors identified 2Health News:Smallest Air Pollution Particles Hurt Heart Most 2Health News:Long-Time San Diego Community Leader, Transplant Patient, Joe Dolphin, Endorses John Mccain 2Health News:Mislabeled Supplement Spurred Prostate Cancer: Report 2Health News:Mislabeled Supplement Spurred Prostate Cancer: Report 3
(Date:1/23/2015)... 23, 2015  Pete Rose, baseball,s all-time hits leader, is the ... reliever Myoflex, Ducere Pharma has announced. "Pete,s a ... to have him on board with Myoflex," said Ducere Pharma ... legendary player who is known across all generations. The passion ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... in Blood Glucose,Control and Progressive Weight Loss ... Amylin,Pharmaceuticals, Inc. and Eli Lilly and Company ... BYETTA(R) (exenatide) injection,sustained improvements in blood sugar ... a half years of therapy. BYETTA treatment,was ...
... Results for,SB-509 in Development for Treatment of ... -- Sangamo,BioSciences, Inc. announced today the presentation ... ZFP Therapeutic(TM) program at the,67th Scientific Sessions ... in an oral presentation entitled, "Improved,Neurologic Exam ...
Cached Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: